Literature DB >> 21784521

Inhibition of K562 leukemia angiogenesis and growth by selective Na+/H+ exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF.

Wei Gao1, Guoqiang Chang, Jian Wang, Weina Jin, Lihong Wang, Yani Lin, Huawen Li, Li Ma, Qinghua Li, Tianxiang Pang.   

Abstract

To investigate the effect of inhibition of Na(+)/H(+) exchanger isoform1 (NHE1) on K562 leukemia-driven angiogenesis, the selective NHE1 inhibitor cariporide was used. Cariporide treatment of K562 resulted in a decrease in pHi and down-regulation of VEGF secretion. The proliferation, migration and in vitro tube formation of human umbilical vein endothelial cells was decreased in cariporide treated K562 condition medium (CM) while VEGF supplement could partially restore the inhibitory effect. Subcutaneous injection of nude mice with cariporide inhibited K562 tumor growth with a reduction of the density of microvessels compared to the control group.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784521     DOI: 10.1016/j.leukres.2011.07.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  Brain tumor acidification using drugs simultaneously targeting multiple pH regulatory mechanisms.

Authors:  Mohammed Albatany; Valeriy G Ostapchenko; Susan Meakin; Robert Bartha
Journal:  J Neurooncol       Date:  2019-08-07       Impact factor: 4.130

2.  Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.

Authors:  Le Shi; Fan Yang; Fei Luo; Yi Liu; Feng Zhang; Meijuan Zou; Qizhan Liu
Journal:  Tumour Biol       Date:  2016-07-23

Review 3.  Functional properties of ion channels and transporters in tumour vascularization.

Authors:  Alessandra Fiorio Pla; Luca Munaron
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-02-03       Impact factor: 6.237

4.  In vivo detection of acute intracellular acidification in glioblastoma multiforme following a single dose of cariporide.

Authors:  Mohammed Albatany; Alex Li; Susan Meakin; Robert Bartha
Journal:  Int J Clin Oncol       Date:  2018-05-10       Impact factor: 3.402

5.  Tumor microenvironment conditions alter Akt and Na+/H+ exchanger NHE1 expression in endothelial cells more than hypoxia alone: implications for endothelial cell function in cancer.

Authors:  A K Pedersen; J Mendes Lopes de Melo; N Mørup; K Tritsaris; S F Pedersen
Journal:  BMC Cancer       Date:  2017-08-14       Impact factor: 4.430

Review 6.  Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer.

Authors:  Tomas Koltai; Rosa A Cardone; Stephan J Reshkin
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

7.  Targeting the pH Paradigm at the Bedside: A Practical Approach.

Authors:  Tomas Koltai
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

Review 8.  Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research.

Authors:  Salvador Harguindey; Jose Luis Arranz; Julian David Polo Orozco; Cyril Rauch; Stefano Fais; Rosa Angela Cardone; Stephan J Reshkin
Journal:  J Transl Med       Date:  2013-11-06       Impact factor: 5.531

9.  Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model.

Authors:  Kodappully Sivaraman Siveen; Kwang Seok Ahn; Tina H Ong; Muthu K Shanmugam; Feng Li; Wei Ney Yap; Alan Prem Kumar; Chee Wai Fong; Vinay Tergaonkar; Kam M Hui; Gautam Sethi
Journal:  Oncotarget       Date:  2014-04-15

10.  S-Nitrosylation of Akt by organic nitrate delays revascularization and the recovery of cardiac function in mice following myocardial infarction.

Authors:  Xiao-Yan Li; Hong-Ming Zhang; Gui-Peng An; Mo-Yan Liu; Shu-Fang Han; Qun Jin; Ying Song; Yi-Meng Lin; Bo Dong; Shuang-Xi Wang; Ling-Bo Meng
Journal:  J Cell Mol Med       Date:  2020-10-30       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.